REDWOOD CITY, Calif.--(EON: Enhanced Online News)--Relypsa, Inc., a clinical-stage biopharmaceutical company, today announced that the American Society of Nephrology (ASN) has accepted its abstract for the late-breaking clinical trial poster session of the ASN Kidney Week 2013 Annual Meeting in Atlanta, GA.
“A Two-Part Trial of Patiromer for the Treatment of Hyperkalemia in Chronic Kidney Disease Subjects on Renin Angiotensin Aldosterone System Inhibition”
The abstract, #5821, entitled, “A Two-Part Trial of Patiromer for the Treatment of Hyperkalemia in Chronic Kidney Disease Subjects on Renin Angiotensin Aldosterone System Inhibition,” will be presented, as follows:
Session Title: Late-Breaking Posters
Session Date, Time: Saturday, November 9, 2013, 10:00 a.m. – 12:00 noon
Poster Board #: SA-PO1085
Lead author, Dr. Matthew Weir, Professor and Director, Division of Nephrology, University of Maryland School of Medicine, Baltimore, MD, will be present at the session.
About Relypsa, Inc.
Relypsa, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company’s two-part pivotal Phase 3 trial of its lead product candidate, patiromer, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood, has been completed and the primary and secondary endpoints were met. Relypsa has global royalty-free commercialization rights to patiromer, which has intellectual property protection in the U.S. until at least 2030. More information is available at www.relypsa.com.